Journal of Clinical Orthopaedics | Vol 5 | Issue 2 | July-Dec 2020 | page: 25-29 | Kadek Mercu Narapati Pamungkas, Putu Itta Sandi Lesmana Dewi, Made Agus Maharjana
Author: Kadek Mercu Narapati Pamungkas , Putu Itta Sandi Lesmana Dewi , Made Agus Maharjana 
 Bachelor of Medicine and Medical Doctor Profession Study Program of Udayana University, Indonesia
 Department of Orthopedics and Traumatology, Faculty of Medicine, Udayana University- Sanglah General Hospital, Indonesia
Address of Correspondence
Dr. Kadek Mercu Narapati Pamungkas,
Bachelor of Medicine and Medical Doctor Profession Study Program of Udayana University, Indonesia
Background: Osteoporosis is a degenerative bone disease that occurs around 15.3% in Southeast Asia. Osteoporosis patients are very vulnerable and often experience fragility fractures. Until now, the treatment of fragility fractures, namely pharmacological and operative therapy, has not been optimal in restoring bone density and allowing recurrence.
Purpose: The aim of this research is to find the modality of therapy fragility fracture that can prevent and improve the condition. Methods: This literature was prepared using literature review methods being sourced from valid medical journals such as published in PubMed, Research Gate, and Google Scholar.
Results: Hesperetin in citrus fruit can inhibit RANKL-induced osteoclastogenesis, reduce the amount and size of F-actin, and accelerate fracture healing in vivo. Vitamin C, which is also present in citrus fruit, has an important role in the synthesis of the triple helix collagen and shows better fracture healing at week 4. PLGA has a role in more specific drug delivery, preventing rapid clearance, biodegradable, increasing calcium deposition, and extending drug release time.
Conclusion: Combination of Hesperetin and PLGA-based vitamin C can be promising therapies in the healing and prevention of fragility fractures. Suggestion: The author suggests conducting further research to determine side effects, proper dosage, and drug administration.
Keywords: Fragility Fracture, Hesperetin, PLGA, Vitamin C
1. Jilka RL. Biology of the basic multicellular unit and the pathophysiology of osteoporosis. Med Pediatr Oncol. 2003;41(3):182–185. https://doi.org/10.1002/mpo.10334
2. Kementerian Kesehatan RI. Info Datin: Pusat data dan informasi kementerian Kesehatan RI. 2015. ISSN 2442-7659.
3. Noor Z, Sumitro SB, Hidayat M, Rahim A., Sabarudin A, Umemura T. Atomic mineral characteristics of Indonesian osteoporosis by high-resolution Inductively coupled plasma mass spectrometry. ScientificWorldJournal. 2012; 372972. doi: 10.1100/2012/372972.
4. PEROSI. Indonesian Osteoporosis: Fact, Figures, and Hopes. Indonesian Osteoporosis Association. 2009
5. Bolton JM, Targownik, LE, Leung S, Sareen J, Leslie WD. Risk of low bone mineral density associated with psychotropic medications and mental disorders in postmenopausal women. J Clin Psychopharmacol. 2011;Feb;31(1):56-60.
6. International Osteoporosis Foundation (IOF). What is Osteoporosis?. [cited Jan, 2020]; Available from: https://www.iofbonehealth.org/what-is-osteoporosis.
7. Cheung et al., An updated panggul fracture projection in Asia: The Asian Federation of Osteoporosis Societies study. Osteoporosis and sarcopenia. 2018;4(1):16-21
8. Levin VA, Jiang X, and Kagan R. Estrogen therapy for osteoporosis in the modern era. Osteoporos Int. 2018:29(5): 1049-1055.
9. Silveira JQ, Cesar TB, Manthey JA, Baldwin EA, Bai J, Raithore S. Pharmacokinetics of flavanone glycosides after ingestion of single doses of fresh-squeezed orange juice versus commercially processed orange juice in healthy humans. J. Agric. Food Chem. 2014;62:12576–12584. doi: 10.1021/jf5 038163
10. Klimczak A, Kozlowska U. Mesenchymal Stromal Cells and Tissue-Specific Progenitor Cells: Their Role in Tissue Homeostasis. Stem Cells Int. 2016:4285215.
11. Zhang Q, Tang X, Liu Z, Song X, Peng D, Zhu W, Ouyang Z, Wang W. Hesperetin Prevents Bone Resorption by Inhibiting RANKL-Induced Osteoclastogenesis and Jnk Mediated Irf-3/c-Jun Activation. Front. Pharmacol. 2018;9:1028. doi: 10.3389/fphar.2018.01028
12. Phillips CL, Yeowell HN. Vitamin C, collagen biosynthesis, and aging. In: Packer L, Fuchs J, eds. Vitamin C in health and disease. New York, USA: Marcel Dekker Inc., 1997;205-30.
13. Alcantara-Martos T, Delgado-Martinez AD, Vega MV, Munuera-Martinez L. Effect of vitamin C on the fracture healing in elderly Osteogenic Disorder Shiogoni rats. J Bone Joint Surg [Br]. 2007;89-B:402-7.
14. Fan D, Rosa E, Murphy M et al. .Mesoporous silicon-PLGA composite microspheres for the double controlled release of biomolecules for orthopedic tissue engineering. Advanced Functional Materials. 2012;22(2): 282–293.
15. Blom AW, Warwick D, Whitehouse MR. Apley and Solomon’s System of Orthopaedic and Trauma Tenth Edition. United Kingdom: CRC Press. 2018
16. Xiao W, Wang Y, Pacios S, Li S, Graves DT. Cellular and molecular aspects of bone remodeling. Front Oral Biol. 2016;18:9–16. https://doi.org/10.1159/000351895
17. Tornquist E, Isaksson H, Turunen MJ. Mineralization of cortical bone during maturation and growth in rabbits. J Bone Miner Metab. 2019. https://doi.org/10.1007/s00774-019-01068-y
18. World Health Organization Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. World Health Organ Tech Rep Ser. 1994;843:1–129.
19. Kanis JA, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2013;24:23–57.
20. World Health Organization. Guidelines for preclinical evaluation and clinical trials in osteoporosis. Geneva: World Health Organization. 1998:59.
21. Choi EJ. Antioxidative effects of hesperetin against 7, 12-dimethylbenz(a)anthracene-induced oxidative stress in mice. Life Sci. 2008. 82:1059–1064
22. Choi EJ, Ahn WS. Neuroprotective effects of chronic hesperetin administration in mice. Arch Pharm Res. 2008;31:1457–1462
23. Hirata A, Murakami Y, Shoji M, Kadoma Y, Fujisawa S. Kinetics of radical-scavenging activity of hesperetin and hesperidin and their inhibitory activity on COX-2 expression. Anticancer Res. 2005;25:3367–3374.
24. Jiang C, et al. Lanthanum chloride attenuates osteoclast formation and function via the downregulation of rankl-induced Nf-Kappab and NFATC1 activities. J. Cell Physiol. 2015;231:142–151. doi: 10.1002/jcp.25065
25. Liu H, et al. Hesperetin suppresses RANKL‐induced osteoclastogenesis and ameliorates lipopolysaccharide‐induced bone loss. J Cell Physiol. 2017;234:11009–11022. https://doi.org/10.1002/jcp.27924
26. Xue D, et al. The role of hesperetin on osteogenesis of human mesenchymal stem cells and its function in bone regeneration. Oncotarget. 2017;8(13):21031–43.
27. U.S Department of Agriculture. Agriculture Research Service. FoodData Central. 2019
28. Aghajanian P, Hall S, Wongworawat MD, Mohan S .The roles and mechanisms of actions of vitamin C in bone: new developments. J Bone Miner Res. 2015;30(11):1945–1955. https://doi.org/10. 1002/jbmr.2709
29. Sun Y, et al. Dietary vitamin C intake and the risk of hip fracture : a dose-response meta-analysis. 2017
30. Zeng L, et al. Can Dietary Intake of Vitamin C-Oriented Foods Reduce the Risk of Osteoporosis, Fracture, and BMD Loss? Systematic Review With Meta-Analyses of Recent Studies. Front. Endocrinol. 2020;10:844. doi: 10.3389/fendo.2019.00844
31. Maruli A, Gunawan B, Jusuf AA. The Role of Vitamin C in Enhancement of Fracture Healing in Fracture with Periosteal Stripping at Sprague-Dawley White Rats Femur. 2013;41(1):9–14.
32. Astete C, Sabliov C. Synthesis and characterization of PLGA nanoparticles. J. Biomater. Sci. Polym. Ed. 2006;17(3):247–289
33. Chaubal M. Polylactides/glycolides – excipients for injectable drug delivery and beyond. Drug Deliv. Tech. 2. 2002;34–36.
34. Biondi M, Ungaro F, Quaglia F, Netti P. Controlled drug delivery in tissue engineering. Adv. Drug Del. Rev. 2008;60(2):229–242.
35. Luan X, Bodmeier R. Influence of the poly(lactide-co glycolide) type on the leuprolide release from in situ forming microparticle systems. J. Cont. Rel. 2006; 110(2):266–272.
36. Lu J, et al. Current advances in research and clinical applications of PLGA based nanotechnology. 2009;4(9):325–341.
37. Wang X. et al. Enhanced bone regeneration using an insulin-loaded nano-hydroxyapatite/collagen/PLGA composite scaffold. International journal of nanomedicine. 2018;13:117-27.
|How to Cite this article: Pamungkas KMN, Dewi PISL, Maharjana MA. Potential Combination of Hesperetin and Vitamin C based on PLGA (Poly Lactic-co-Glycolic Acid) on Healing Fragility Fracture in Osteoporosis Patients. Journal of Clinical Orthopaedics July-Dec 2020;5(2):25-29.|